## Antonio Bellasi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1355574/publications.pdf

Version: 2024-02-01

126907 149698 4,005 161 33 56 citations h-index g-index papers 182 182 182 5466 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Mortality in Kidney Disease Patients Treated with Phosphate Binders. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 487-493.	4.5	209
2	Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019. JAMA Cardiology, 2020, 5, 1274.	6.1	157
3	Sevelamer Versus Calcium Carbonate in Incident Hemodialysis Patients: Results of an Open-Label 24-Month Randomized Clinical Trial. American Journal of Kidney Diseases, 2013, 62, 771-778.	1.9	156
4	Chronic Kidney Disease Progression and Outcome According to Serum Phosphorus in Mild-to-Moderate Kidney Dysfunction. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 883-891.	4.5	128
5	International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. Npj Digital Medicine, 2020, 3, 109.	10.9	128
6	Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis, 2008, 199, 424-431.	0.8	114
7	Cardiorenal Syndrome: An Overview. Advances in Chronic Kidney Disease, 2018, 25, 382-390.	1.4	109
8	Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. Journal of Nephrology, 2019, 32, 989-1001.	2.0	104
9	Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis. Circulation, 2020, 141, 728-739.	1.6	104
10	Impact of heart failure on the clinical course and outcomes of patients hospitalized for <scp>COVID</scp> â€19. Results of the <scp>Cardio OVIDâ€Italy</scp> multicentre study. European Journal of Heart Failure, 2020, 22, 2238-2247.	7.1	99
11	All-cause Mortality in Hemodialysis Patients with Heart Valve Calcification. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1990-1995.	4.5	96
12	Comparison of Prognostic Usefulness of Coronary Artery Calcium in Men Versus Women (Results) Tj ETQq0 0 0 rg	gBT /Overl	ock 10 Tf 50 92
13	Investigation of Gender Heterogeneity in the Associations of Serum Phosphorus With Incident Coronary Artery Disease and All-Cause Mortality. American Journal of Epidemiology, 2008, 169, 67-77.	3.4	86
14	Nutritional Therapy Modulates Intestinal Microbiota and Reduces Serum Levels of Total and Free Indoxyl Sulfate and P-Cresyl Sulfate in Chronic Kidney Disease (Medika Study). Journal of Clinical Medicine, 2019, 8, 1424.	2.4	81
15	Pulse Wave Velocity Is Inversely Related to Vertebral Bone Density in Hemodialysis Patients. Hypertension, 2007, 49, 1278-1284.	2.7	73
16	Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients. Nephrology Dialysis Transplantation, 2013, 28, 632-640.	0.7	73
17	Correction of metabolic acidosis improves insulin resistance in chronic kidney disease. BMC Nephrology, 2016, 17, 158.	1.8	66
18	Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrology Dialysis Transplantation, 2006, 21, 3215-3222.	0.7	65

#	Article	IF	Citations
19	Blood pressure variability and outcomes in chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 4404-4410.	0.7	64
20	Combined Impact of Age and Estimated Glomerular Filtration Rate on In-Hospital Mortality After Percutaneous Coronary Intervention for Acute Myocardial Infarction (from the American College of) Tj ETQq0	0 0 rgBT /Ov	verl <b>o</b> ck 10 Tf 5
21	Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 26-33.	3.3	49
22	Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease. CKJ: Clinical Kidney Journal, 2015, 8, 732-736.	2.9	46
23	Nutritional therapy reduces protein carbamylation through urea lowering in chronic kidney disease. Nephrology Dialysis Transplantation, 2018, 33, 804-813.	0.7	45
24	Cardiorenal Syndrome in Acute Kidney Injury. Seminars in Nephrology, 2019, 39, 31-40.	1.6	45
25	Phosphate binders: New products and challenges. Hemodialysis International, 2006, 10, 225-234.	0.9	44
26	Coronary Artery Calcification Progression Is Associated with Arterial Stiffness and Cardiac Repolarization Deterioration in Hemodialysis Patients. Kidney and Blood Pressure Research, 2011, 34, 180-187.	2.0	42
27	Cardiac valve calcification and use of anticoagulants: Preliminary observation of a potentially modifiable risk factor. International Journal of Cardiology, 2019, 278, 243-249.	1.7	41
28	Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial. Nephrology Dialysis Transplantation, 2013, 28, 2586-2595.	0.7	39
29	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Techniques and Technologies to Assess Vascular Calcification. Seminars in Dialysis, 2007, 20, 129-133.	1.3	38
30	Cardiorenal acute kidney injury: Epidemiology, presentation, causes, pathophysiology and treatment. International Journal of Cardiology, 2017, 227, 143-150.	1.7	37
31	Cardiovascular Biomarkers in Chronic Kidney Disease: State of Current Research and Clinical Applicability. Disease Markers, 2015, 2015, 1-16.	1.3	36
32	New insights into ischemic heart disease in women Cleveland Clinic Journal of Medicine, 2007, 74, 585-594.	1.3	36
33	Kidney Disease in HIV Infection. Journal of Clinical Medicine, 2019, 8, 1254.	2.4	35
34	Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study. Europace, 2021, 23, 1603-1611.	1.7	34
35	Cardiac valve calcification is a marker of vascular disease in prevalent hemodialysis patients. Journal of Nephrology, 2012, 25, 211-218.	2.0	34
36	Vascular imaging in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2012, 21, 382-388.	2.0	33

#	Article	IF	CITATIONS
37	Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease. Journal of Nephrology, 2015, 28, 73-80.	2.0	33
38	International Analysis of Electronic Health Records of Children and Youth Hospitalized With COVID-19 Infection in 6 Countries. JAMA Network Open, 2021, 4, e2112596.	5.9	33
39	Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data. Journal of Nephrology, 2018, 31, 751-756.	2.0	32
40	Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study. Clinical Research in Cardiology, 2021, 110, 1020-1028.	3.3	32
41	Epicardial adipose tissue and coronary artery calcium predict incident myocardial infarction and death in HIV-infected patients. Journal of Cardiovascular Computed Tomography, 2015, 9, 553-558.	1.3	31
42	How long is the warranty period for nil or low coronary artery calcium in patients new to hemodialysis?. Journal of Nephrology, 2009, 22, 255-62.	2.0	31
43	Ischemia Imaging and Plaque Imaging in Diabetes: Complementary tools to improve cardiovascular risk management. Diabetes Care, 2005, 28, 2787-2794.	8.6	29
44	Clinical Assessment of Vascular Calcification. Advances in Chronic Kidney Disease, 2007, 14, 37-43.	1.4	29
45	The density of calcified plaques and the volume of calcium predict mortality in hemodialysis patients. Atherosclerosis, 2016, 250, 166-171.	0.8	29
46	Mineral and Electrolyte Disorders With SGLT2i Therapy. JBMR Plus, 2019, 3, e10242.	2.7	28
47	Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide. Therapeutics and Clinical Risk Management, 2017, Volume 13, 679-689.	2.0	27
48	ACE2 (Angiotensin-Converting Enzyme 2) and TMPRSS2 (Transmembrane Serine Protease 2) Expression and Localization of SARS-CoV-2 Infection in the Human Heart. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 542-544.	2.4	27
49	Epidemiology of low-proteinuric chronic kidney disease in renal clinics. PLoS ONE, 2017, 12, e0172241.	2.5	26
50	Development of a cardiovascular calcification index using simple imaging tools in haemodialysis patients. Nephrology Dialysis Transplantation, 2006, 22, 508-514.	0.7	25
51	The prognostic value of serial troponin measurements in patients admitted for COVIDâ€19. ESC Heart Failure, 2021, 8, 3504-3511.	3.1	25
52	Emerging drugs for secondary hyperparathyroidism. Expert Opinion on Emerging Drugs, 2015, 20, 197-208.	2.4	24
53	Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy. Journal of Clinical Medicine, 2021, 10, 83.	2.4	24
54	Diagnostic and prognostic value of coronary artery calcium screening. Current Opinion in Cardiology, 2005, 20, 375-380.	1.8	23

#	Article	IF	Citations
55	Arterial Stiffness in Chronic Kidney Disease: The Usefulness of a Marker of Vascular Damage. International Journal of Nephrology, 2011, 2011, 1-5.	1.3	22
56	Which Vitamin D in CKD-MBD? The Time of Burning Questions. BioMed Research International, 2013, 2013, 1-10.	1.9	22
57	Hybrid myocardial imaging for risk stratification prior to kidney transplantation: Added value of coronary calcium and epicardial adipose tissue. Journal of Nuclear Cardiology, 2013, 20, 1013-1020.	2.1	21
58	Prediction of hard cardiovascular events in HIV patients. Journal of Antimicrobial Chemotherapy, 2016, 71, 3515-3518.	3.0	20
59	Vascular calcification in chronic kidney disease: usefulness of a marker of vascular damage. Journal of Nephrology, 2011, 24, 11-15.	2.0	20
60	Presence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE study. Journal of Heart Valve Disease, 2013, 22, 391-9.	0.5	20
61	Chronic Hyperkalemia in Cardiorenal Patients: Risk Factors, Diagnosis, and New Treatment Options. CardioRenal Medicine, 2019, 9, 8-21.	1.9	19
62	International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: Retrospective Cohort Study. Journal of Medical Internet Research, 2021, 23, e31400.	4.3	19
63	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. American Journal of Kidney Diseases, 2019, 74, 338-350.	1.9	17
64	Vitamin D Status and Coronary Flow Reserve Measured by Positron Emission Tomography: A Co-Twin Control Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 389-397.	3.6	16
65	The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, S295-S305.	3.6	16
66	Osteocalcin (bone GLA protein) levels, vascular calcifications, vertebral fractures and mortality in hemodialysis patients with diabetes mellitus. Journal of Nephrology, 2019, 32, 635-643.	2.0	16
67	QT interval in CKD and haemodialysis patients. CKJ: Clinical Kidney Journal, 2013, 6, 137-143.	2.9	15
68	Implication of Acute Kidney Injury in Heart Failure. Heart Failure Clinics, 2019, 15, 463-476.	2.1	15
69	English–Latin nomenclature conundrum: should we use kidneylogy, kidneylogist?. Kidney International, 2020, 98, 1352-1353.	5.2	15
70	Sevelamer Use, Vitamin K Levels, Vascular Calcifications, and Vertebral Fractures in Hemodialysis Patients: Results from the VIKI Study. Journal of Bone and Mineral Research, 2020, 36, 500-509.	2.8	15
71	Arterial Accelerated Aging in Dialysis Patients: The Clinical Impact of Vascular Calcification. Current Vascular Pharmacology, 2009, 7, 374-380.	1.7	14
72	Does It Make Sense to Measure Only the Brachial Blood Pressure?. Blood Purification, 2013, 36, 21-25.	1.8	14

#	Article	IF	Citations
73	Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease. Expert Review of Clinical Pharmacology, 2017, 10, 1073-1084.	3.1	14
74	Nutritional therapy in autosomal dominant polycystic kidney disease. Journal of Nephrology, 2018, 31, 635-643.	2.0	14
75	Chronic Kidney Disease: The Silent Epidemy. Journal of Clinical Medicine, 2019, 8, 1795.	2.4	14
76	Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network. CardioRenal Medicine, 2020, 10, 266-276.	1.9	14
77	Vascular calcification, bone and mineral metabolism after kidney transplantation. World Journal of Transplantation, 2015, 5, 222.	1.6	14
78	Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the) Tj ETQ	1900 pg opl	3T /Overlock 1
79	Variability of pulse wave velocity and mortality in chronic hemodialysis patients. Hemodialysis International, 2011, 15, 326-333.	0.9	13
80	Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator?. International Journal of Cardiology, 2019, 274, 179-185.	1.7	13
81	Sevelamer Is Cost-Saving vs. Calcium Carbonate in Non-Dialysis-Dependent CKD Patients in Italy: A Patient-Level Cost-Effectiveness Analysis of the INDEPENDENT Study. Blood Purification, 2014, 37, 316-324.	1.8	11
82	Pro: Should phosphate binders be used in chronic kidney disease stage 3–4?Opponent's comments. Nephrology Dialysis Transplantation, 2016, 31, gfv405.	0.7	11
83	Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study. Journal of Nephrology, 2015, 28, 593-602.	2.0	11
84	Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium-based phosphate binders: a substudy of the Renagel in new dialysis trial. Journal of Nephrology, 2016, 29, 683-690.	2.0	11
85	Cardiovascular calcification: The emerging role of micronutrients. Atherosclerosis, 2018, 273, 119-121.	0.8	11
86	Assessment of intradialysis calcium mass balance by a single pool variableâ€volume calcium kinetic model. Hemodialysis International, 2018, 22, 126-135.	0.9	11
87	Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis â€" Subgroup Analyses of the CALIPSO Trial. Kidney International Reports, 2020, 5, 2178-2182.	0.8	11
88	Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 736-745.	4.5	11
89	Phosphate binders in moderate chronic kidney disease: where do we stand?. Journal of Nephrology, 2013, 26, 993-1000.	2.0	11
90	New evidence of direct oral anticoagulation therapy on cardiac valve calcifications, renal preservation and inflammatory modulation. International Journal of Cardiology, 2021, 345, 90-97.	1.7	11

#	Article	IF	Citations
91	Integration of clinical and imaging data to predict death in hemodialysis patients. Hemodialysis International, 2013, 17, 12-18.	0.9	10
92	Very Low Protein Diet for Patients with Chronic Kidney Disease: Recent Insights. Journal of Clinical Medicine, 2019, 8, 718.	2.4	10
93	Predictive Value of Measures of Vascular Calcification Burden and Progression for Risk of Death in Incident to Dialysis Patients. Journal of Clinical Medicine, 2021, 10, 376.	2.4	10
94	Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19. Scientific Reports, 2021, 11, 20238.	3.3	10
95	Impact of race and chronic kidney disease on 1-year outcome in patients undergoing percutaneous coronary interventions: A single tertiary center experience. American Heart Journal, 2008, 155, 1027-1032.	2.7	9
96	Is time on cardiopulmonary bypass during cardiac surgery associated with acute kidney injury requiring dialysis?. Hemodialysis International, 2012, 16, 252-258.	0.9	9
97	New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology. Journal of Nephrology, 2020, 33, 211-221.	2.0	9
98	Cinacalcet but not vitamin D use modulates the survival benefit associated with sevelamer in the INDEPENDENT study. Clinical Nephrology, 2016, 86, 113-124.	0.7	9
99	Inverse Correlation Between Vascular Calcification and Bone Mineral Density in Human Immunodeficiency Virus-Infected Patients. Calcified Tissue International, 2013, 93, 413-418.	3.1	8
100	Fractional Excretion of Phosphate (FeP) Is Associated with End-Stage Renal Disease Patients with CKD 3b and 5. Journal of Clinical Medicine, 2019, 8, 1026.	2.4	8
101	Therapeutic management of HIV-infected patients with chronic kidney disease. Journal of Nephrology, 2020, 33, 699-713.	2.0	8
102	Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification. CKJ: Clinical Kidney Journal, 2021, 14, 366-374.	2.9	8
103	International comparisons of laboratory values from the 4CE collaborative to predict COVID-19 mortality. Npj Digital Medicine, 2022, 5, .	10.9	7
104	Intact parathyroid hormone levels are associated with increased carotid intima media thickness in HIV infected patients. Atherosclerosis, 2014, 237, 618-622.	0.8	6
105	Con: Phosphate binders in chronic kidney diseaseOpponent's comments. Nephrology Dialysis Transplantation, 2016, 31, gfv406.	0.7	6
106	Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19. International Journal of Infectious Diseases, 2021, 108, 270-273.	3.3	6
107	Bone Mineral Density Changes in Long-Term Kidney Transplant Recipients: A Real-Life Cohort Study of Native Vitamin D Supplementation. Nutrients, 2022, 14, 323.	4.1	6
108	Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study. Journal of Cardiovascular Medicine, 2022, 23, 439-446.	1.5	6

#	Article	IF	CITATIONS
109	Cinacalcet: the chemical parathyroidectomy?. CKJ: Clinical Kidney Journal, 2013, 6, 253-256.	2.9	5
110	Vascular Calcification Progression Modulates the Risk Associated with Vascular Calcification Burden in Incident to Dialysis Patients. Cells, 2021, 10, 1091.	4.1	5
111	Overweight-obesity is associated with decreased vitamin K2 levels in hemodialysis patients. Clinical Chemistry and Laboratory Medicine, 2021, 59, 581-589.	2.3	5
112	What can we learn from a statistically inconclusive trial? Consensus conference on the EVOLVE study results. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Società Italiana Di Nefrologia, 2013, 30, .	0.3	5
113	Ethiopathogenesis, Diagnosis and Prevention of Vascular Calcification in End Stage Renal Disease. Current Medicinal Chemistry Cardiovascular and Hematological Agents, 2005, 3, 165-171.	1.7	4
114	CKD-MBD management: what is the role of parathyroidectomy? Results from a nationwide survey in Italy. Journal of Nephrology, 2018, 31, 585-591.	2.0	4
115	Vascular inflammation: A call for a specific and sensitive biomarker?. Atherosclerosis, 2018, 271, 235-236.	0.8	4
116	Among markers of risk, uric acid remains a two-faced Janus awaiting definitive framing. Atherosclerosis, 2018, 272, 219-221.	0.8	4
117	Vitamin D Metabolism and Potential Effects of Vitamin D Receptor Modulation in Chronic Kidney Disease. Current Drug Metabolism, 2017, 18, 680-688.	1.2	4
118	The Connubium among diabetes, chronic kidney disease and atrial fibrillation. Minerva Cardiology and Angiology, 2022, , .	0.7	4
119	Impact of Vascular Calcification on QT Interval and QT Dispersion in CKD and Dialysis Patients. American Journal of Nephrology, 2012, 35, 287-287.	3.1	3
120	Not all diabetic patients were created equal: How to discriminate risk?. Atherosclerosis, 2014, 237, 82-83.	0.8	3
121	Ivabradine, Heart Failure and Chronic Kidney Disease. Nephrology @ Point of Care, 2015, 1, poc.5000190.	0.2	3
122	Search for a reliable biomarker of acute kidney injury: to the heart of the problem. Annals of Translational Medicine, 2018, 6, S5-S5.	1.7	3
123	Feasibility of routine ultrasound-guided percutaneous transluminal angioplasty in the treatment of native arteriovenous fistula dysfunction. Journal of Vascular Access, 2020, 22, 112972982094307.	0.9	3
124	Is peritoneal dialysis superior to hemodialysis as far as cardiovascular risk? Another unsolved dilemma for maintenance dialysis. Atherosclerosis, 2020, 307, 75-77.	0.8	3
125	Bone metabolism and cardiovascular disease: An overlooked association?. Atherosclerosis, 2021, 335, 87-88.	0.8	3
126	Cardiac valve calcification: an immutable pathologic finding in chronic kidney disease?. Journal of Nephrology, 2013, 26, 606-609.	2.0	3

#	Article	IF	Citations
127	New insights into ischemic heart disease in women. Journal of the California Dental Association, 2008, 36, 107-14.	0.1	3
128	[Penultimate pulse wave velocity, better than baseline pulse wave velocity, predicted mortality in Italian ESRD cohort study - a case for daily hemodialysis for ESRD patients with accelerated pulse wave velocity changes]. Giornale Italiano Di Nefrologia: Organo Ufficiale Della Società Italiana Di Nefrologia, 2013, 30, .	0.3	3
129	Physical Activity in Chronic Kidney Disease: a Plausible Approach to Vascular Calcification?. Kidney and Blood Pressure Research, 2014, 39, 154-163.	2.0	2
130	Chronic kidney disease: A model of impaired vascular remodeling. Atherosclerosis, 2018, 279, 88-90.	0.8	2
131	Associations of Calcium from Food Sources versus Phosphate Binders with Serum Calcium and FGF23 in Hemodialysis Patients. Journal of Clinical Medicine, 2019, 8, 1680.	2.4	2
132	Lipid-lowering therapy with statins in postmenopausal women: a few answered and many unanswered questions. Future Lipidology, $2006$ , $1$ , $375-379$ .	0.5	1
133	Paricalcitol and Cardiorenal Outcome: From the IMPACT Study to Clinical Practice. Blood Purification, 2013, 36, 12-16.	1.8	1
134	Phosphate Metabolism Modulation in Chronic Kidney Disease: When, How and to What Extent?. Nephro-Urology Monthly, 2014, 6, e18379.	0.1	1
135	Urolithiasis associated with atazanavir may mask a metabolic 'channelling' bias. Journal of Antimicrobial Chemotherapy, 2014, 69, 284-285.	3.0	1
136	The Importance of Ventricular-Vascular Uncoupling. JACC: Heart Failure, 2015, 3, 95.	4.1	1
137	Coronary artery disease (CAD) in chronic kidney disease patients. Giornale De Techniche Nefrologiche & Dialitiche, 2016, 28, 44-52.	0.1	1
138	Retarding CKD Progression: Readily Available through Comprehensive Nutritional Management?. Nephrology @ Point of Care, 2016, 2, pocj.5000202.	0.2	1
139	Serum calcium may not accurately predict intradialytic calcium mass transfer. Hemodialysis International, 2016, 20, 331-332.	0.9	1
140	Shed a light on intradialytic calcium mass balance. Kidney International, 2016, 89, 1402.	5.2	1
141	Opponent's comments. Nephrology Dialysis Transplantation, 2016, 31, 194-195.	0.7	1
142	Type-5 Cardiorenal Syndrome (CRS-5): An up to Date. Nephrology @ Point of Care, 2017, 3, napoc.5000212.	0.2	1
143	Associations between echocardiographic findings and prospective changes in residual renal function in patients new to peritoneal dialysis. Scientific Reports, 2019, 9, 18434.	3 <b>.</b> 3	1
144	Retinal endothelial dysfunction: A glance on long-term risk of kidney failure. Atherosclerosis, 2022, 341, 50-51.	0.8	1

#	Article	IF	Citations
145	The "FIFTY SHADOWS―of the RALES Trial: Lessons about the Potential Risk of Dietary Potassium Supplementation in Patients with Chronic Kidney Disease. Journal of Clinical Medicine, 2022, 11, 3970.	2.4	1
146	Review: Imaging to assess effect of medical therapy in patients with diabetes mellitus. British Journal of Diabetes and Vascular Disease, 2007, 7, 157-164.	0.6	0
147	Arterial Stiffness, Pulse Wave Analyses: What Can't Blood Pressure Tell you in Chronic Kidney Disease. Current Hypertension Reviews, 2012, 8, 244-249.	0.9	0
148	Nephrology@Point of Care: A New Journal for Hands-On Clinicians. Nephrology @ Point of Care, 2015, 1, napoc.2015.1468.	0.2	0
149	SP575PREDICTIVE VALUE OF MEASURES OF VASCULAR CALCIFICATION FOR RISK OF DEATH IN INCIDENT DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii568-iii568.	0.7	0
150	Single-Center Open-Label Randomized Study of Anemia Management Improvement in ESRD Patients with Secondary Hyperparathyroidism. Nephrology @ Point of Care, 2016, 2, pocj.5000196.	0.2	0
151	Phosphate Management in Patients With End-Stage Renal Disease. , 2017, , 698-705.e2.		0
152	Coronary artery calcium in the general population, patients with chronic kidney disease and diabetes mellitus., 2019,, 159-180.		0
153	Ultrafiltrazione peritoneale e sindrome cardiorenale: gestione del sovraccarico di fluidi e ruolo del sodio. Giornale De Techniche Nefrologiche & Dialitiche, 2019, 31, 100-105.	0.1	0
154	Rivaroxaban e malattia renale cronica: evidenze dal presente e prospettive future. Giornale De Techniche Nefrologiche & Dialitiche, 2019, 31, 30-36.	0.1	0
155	Cardiovascular Calcium: Assessment and Impact of Interventions. , 2008, , 1-6.		0
156	Arterial Stiffness, Pulse Wave Analyses: What Can't Blood Pressure Tell you in Chronic Kidney Disease. Current Hypertension Reviews, 2012, 8, 244-249.	0.9	0
157	Phosphate Balance and Organ Damage. Giornale De Techniche Nefrologiche & Dialitiche, 2013, 25, 208-212.	0.1	0
158	Vitamina D nativa o attivata: quale forma $\tilde{A}^{\cdot \cdot}$ indispensabile?. Giornale De Techniche Nefrologiche & Dialitiche, 2015, 27, 143-144.	0.1	0
159	Kidney Diseases: Challenges and Opportunities of the Third Millenium. How can digital health help the National Health System?. AboutOpen, 2020, 7, 1-3.	0.2	0
160	Glifozines and cardiorenal outcomes. Minerva Cardioangiologica, 2020, 68, 188-196.	1,2	0
161	Twelve-lead electrocardiogram artefacts in patients with arteriovenous fistulas for haemodialysis. European Heart Journal - Case Reports, 2021, 5, ytab466.	0.6	0